RNA-based viral vectors (Q38266413)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	RNA-based viral vectors	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

RNA-based viral vectors (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

0 references

author name string

Mark A Mogler

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Kurt I Kamrud

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

publication date

8 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Expert Review of Vaccines

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

283-312

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Lentiviral vectors: a versatile tool to fight cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Alphavirus vectors and vaccination

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Alphavirus replicon vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A chimeric Sindbis-based vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric alphavirus vaccine candidates for chikungunya

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Characterization of untranslated regions of the salmonid alphavirus 3 (SAV3) genome and construction of a SAV3 based replicon

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recovery of a recombinant salmonid alphavirus fully attenuated and protective for rainbow trout

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Salmonid alphavirus-based replicon vaccine against infectious salmon anemia (ISA): impact of immunization route and interactions of the replicon vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Research on basis of reverse genetics system of a Sindbis-like virus XJ-160

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Viral and Non-viral Vectors in Gene Therapy: Technology Development and Clinical Trials

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Biology and application of alphaviruses in gene therapy

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Alphavirus replicon particles as candidate HIV vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Characterization and selection of HIV-1 subtype C isolates for use in vaccine development

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Myristoylation-dependent replication and assembly of human immunodeficiency virus 1

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development and preclinical evaluation of an alphavirus replicon vaccine for influenza

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Safety, immunogenicity, and efficacy of an alphavirus replicon-based swine influenza virus hemagglutinin vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Yellow fever 17D as a vaccine vector for microbial CTL epitopes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development of a live attenuated dengue virus vaccine using reverse genetics

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric Langat/Dengue viruses protect mice from heterologous challenge with the highly virulent strains of tick-borne encephalitis virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Production and characterization of vaccines based on flaviviruses defective in replication

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Single-dose vaccine against tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Production of Pseudoinfectious Yellow Fever Virus with a Two-Component Genome

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Internal ribosome entry site-based attenuation of a flavivirus candidate vaccine and evaluation of the effect of beta interferon coexpression on vaccine properties

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Approved and experimental countermeasures against pestiviral diseases: Bovine viral diarrhea, classical swine fever and border disease

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

An avirulent chimeric Pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

CP7_E2alf: a safe and efficient marker vaccine strain for oral immunisation of wild boar against Classical swine fever virus (CSFV).

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Efficacy of chimeric Pestivirus vaccine candidates against classical swine fever: protection and DIVA characteristics

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

CP7_E2alf oral vaccination confers partial protection against early classical swine fever virus challenge and interferes with pathogeny-related cytokine responses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

First assessment of classical swine fever marker vaccine candidate CP7_E2alf for oral immunization of wild boar under field conditions

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Characterization of a new chimeric marker vaccine candidate with a mutated antigenic E2-epitope

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Virulence, immunogenicity and vaccine properties of a novel chimeric pestivirus.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

DIVA vaccine properties of the live chimeric pestivirus strain CP7_E2gif

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Bovine viral diarrhea virus is a suitable viral vector for stable expression of heterologous gene when inserted in between N(pro) and C genes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Construction of chimeric bovine viral diarrhea viruses containing glycoprotein E rns of heterologous pestiviruses and evaluation of the chimeras as potential marker vaccines against BVDV.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric classical swine fever (CSF)-Japanese encephalitis (JE) viral replicon as a non-transmissible vaccine candidate against CSF and JE infections

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Amplification, expression, and packaging of foreign gene by influenza virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Introduction of site-specific mutations into the genome of influenza virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Characterization of influenza virus NS1 protein by using a novel helper-virus-free reverse genetic system

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A DNA transfection system for generation of influenza A virus from eight plasmids

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Generation of influenza A viruses entirely from cloned cDNAs

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Plasmid-driven formation of influenza virus-like particles

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

RNA polymerase I-mediated expression of influenza viral RNA molecules

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Exploring mucosal immunization with a recombinant influenza virus carrying an HIV-polyepitope in mice with pre-existing immunity to influenza

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Live bivalent vaccine for parainfluenza and influenza virus infections

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Characterization of recombinant influenza A virus as a vector expressing respiratory syncytial virus fusion protein epitopes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Synthetic generation of influenza vaccine viruses for rapid response to pandemics

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Enzymatic assembly of overlapping DNA fragments

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Cells that express all five proteins of vesicular stomatitis virus from cloned cDNAs support replication, assembly, and budding of defective interfering particles.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for va

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant vesicular stomatitis viruses from DNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Rabies virus nucleoprotein as a carrier for foreign antigens.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Oral vaccination of dogs with recombinant rabies virus vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Rabies virus as a research tool and viral vaccine vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant rabies virus as potential live-viral vaccines for HIV-1.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Characterization of a single-cycle rabies virus-based vaccine vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

New rabies virus variants for monitoring and manipulating activity and gene expression in defined neural circuits

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Vesicular stomatitis virus: re-inventing the bullet

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Nonsegmented negative-strand viruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Construction of a Novel Virus That Targets HIV-1-Infected Cells and Controls HIV-1 Infection

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluating Replication-Defective Vesicular Stomatitis Virus as a Vaccine Vehicle

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A chimeric vesiculo/alphavirus is an effective alphavirus vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Expression and processing of human immunodeficiency virus type 1 gp160 using the vesicular stomatitis virus New Jersey serotype vector system

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A recombinant novirhabdovirus presenting at the surface the E Glycoprotein from West Nile Virus (WNV) is immunogenic and provides partial protection against lethal WNV challenge in BALB/c mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Diagnosis and clinical significance of parainfluenza virus infections in children

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recent developments with live-attenuated recombinant paramyxovirus vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and Children

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Efficient gene transfer to airway epithelium using recombinant Sendai virus.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Sendai virus-based RSV vaccine protects African green monkeys from RSV infection

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Primary replication of a recombinant Sendai virus vector in macaques

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Elicitation of protective immunity against simian immunodeficiency virus infection by a recombinant Sendai virus expressing the Gag protein

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistanc

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A perspective view of sodium iodide symporter research and its clinical implications

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A paediatric vaccination vector based on live attenuated measles vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunogenicity of a recombinant measles HIV-1 subtype C vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Attenuated measles virus as a vaccine vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Rescue of mumps virus from cDNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recovery of Infectious SV5 from Cloned DNA and Expression of a Foreign Gene

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

High avidity cytotoxic T lymphocytes to a foreign antigen are efficiently activated following immunization with a recombinant paramyxovirus, simian virus 5.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A newly discovered human pneumovirus isolated from young children with respiratory tract disease

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Human metapneumovirus: a new player among respiratory viruses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recovery of avian metapneumovirus subgroup C from cDNA: cross-recognition of avian and human metapneumovirus support proteins

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Generation of recombinant lentogenic Newcastle disease virus from cDNA.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant Newcastle disease virus as a vaccine vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A Respiratory Syncytial Virus Replicon That Is Noncytotoxic and Capable of Long-Term Foreign Gene Expression

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Induction of humoral and cellular immune responses against hepatitis C virus by vaccination with replicon particles derived from Sindbis-like virus XJ-160.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Haemagglutinin and nucleoprotein replicon particle vaccination of swine protects against the pandemic H1N1 2009 virus.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development and characterization of the replicon system of Japanese encephalitis live vaccine virus SA14-14-2.

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3' proximal first locus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

The Molecular Biology of Human Respiratory Syncytial Virus (RSV) of the Genus Pneumovirus

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2015.979798

21 January 2018

Identifiers

10.1586/14760584.2015.979798

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38266413&oldid=1751481912"